Meridian Bioscience (NASDAQ: VIVO) reported Q1 EPS of $0.35, $0.10 better than the analyst estimate of $0.25. Revenue for the quarter came in at $88.3 million versus the consensus estimate of $70.29 million.

GUIDANCE:

Meridian Bioscience sees FY2022 EPS of $1.10-$1.30, versus the consensus of $1.04. Meridian Bioscience sees FY2022 revenue of $315-330 million, versus the consensus of $288 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.